Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma
Genvira Biosciences Inc. (“Genvira”), a Canadian innovator in next-generation viral vectors, Labskin Limited (“Labskin”), a leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) are pleased to announce the launch of a collaborative project to develop novel immunotherapies for malignant melanoma. The collaboration is receiving advisory services and up to £1.2 million ($2.0 million) in funding through the Canada–UK Biomanufacturing of Biologics and Advanced Therapies program. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP).
